Skip to content

The comparison among different applications of tranexamic acid in total knee arthroplasty: a single-center, prospective, randomized, double-blind controlled trial

The comparison among different applications of tranexamic acid in total knee arthroplasty.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200060958
Enrollment
Unknown
Registered
2022-06-14
Start date
2022-06-01
Completion date
Unknown
Last updated
2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee osteoarthritis

Interventions

Group A:PAI 1g(10ml)TXA+IAI 20ml NS
Group B:PAI 10ml NS+IAI 2g (20ml) TXA

Sponsors

Xi'an Honghui Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Patients aged 50 to 80 years with primary unilateral or bilateral knee osteoarthritis; 2.Primary unilateral total knee arthroplasty was performed;3.Good physical condition, can tolerate surgery; 4.Preoperative coagulation function of hemoglobin erythrocyte sedimentation rate and C-reactive protein were normal; 5.There was no abnormality in deep vein ultrasonography of both lower limbs pre-operative.

Exclusion criteria

Exclusion criteria: 1) The patient had a history of tranexamic acid allergy; 2) history of thrombosis and oral anticoagulants within two weeks; 3) have ongoing infections in other parts of the body; 4) Hemorrhagic diseases; 5) Atrial fibrillation, angina pectoris, stroke and other internal diseases; 6) Rheumatoid arthritis; 7)TKA revision patients; 8) The patient had a mental illness or refused to participate in the study.

Design outcomes

Primary

MeasureTime frame
blood loss volume;transfusion rate;

Secondary

MeasureTime frame
ROM;VAS;

Countries

China

Contacts

Public ContactJianpeng Wang
280771976@qq.com15802991190

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026